GlassScriptPhysician profile
Frank David Newby
NPI 1801889696
$8,467.97
in general payments reported to CMS, 2019-2025
39 companies · $1,610 in 2025
The $1,610 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,009 · 2020: $823 · 2021: $823 · 2022: $1,296 · 2023: $1,160 · 2024: $1,747 · 2025: $1,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,444 · Education: $73.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,443.70 |
| Education | $73.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $995.52 | 2019-2025 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $898.63 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $845.65 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $725.02 | 2019-2025 | Tavneos |
| Fresenius USA Marketing, INC. | $629.17 | 2019-2025 | Velphoro, Velphoro, Nxstage System One |
| Bayer Healthcare Pharmaceuticals INC. | $623.46 | 2021-2025 | |
| Akebia Therapeutics INC | $507.51 | 2019-2024 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $439.85 | 2020-2025 | Filspari |
| Vifor Pharma, INC. | $362.65 | 2019-2025 | Veltassa, Korsuva |
| Novo Nordisk INC | $312.30 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $251.50 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $208.87 | 2022-2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $207.87 | 2022-2024 | Tarpeyo |
| Ardelyx, INC. | $205.19 | 2023-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $163.95 | 2022-2025 | Acthar |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Newby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.